LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

Home・Listă Acțiuni・Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Deschisă

Sector Sănătate

1,158.07 0.44

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

1151.73

Maxim

1160.91

Indicatori cheie
By Trading Economics
Venit	710M 1.4B
Vânzări	400M 3.6B
P/E Medie Sector	31.03 103.001
EPS	11.56
Marjă de profit	40.346
Angajați	13,450
EBITDA	933M 1.8B

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+2.78 upside

Dividende
By Dow Jones
Următoarele câștiguri	31 oct. 2024

Statistici piață
By TradingEconomics
Capitalizare de piață	130B
Deschiderea anterioară	1157.63
Închiderea anterioară	1158.07

Sentimentul știrilor

By Acuity

59%

41%

284 / 365 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bullish Evidence

1143.245 / 1162.865 Suport & Rezistență

Regeneron Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

8 iul. 2024, 12:00 UTC

Câștiguri

Regeneron Expects Earnings Hit After $24 Million R&D Charge

2 mai 2024, 11:02 UTC

Câștiguri

Regeneron Pharmaceuticals 1Q Revenue Declines Amid Lower EYLEA Sales

2 feb. 2024, 11:59 UTC

Câștiguri

Regeneron's 4Q Sales Edge Higher, Despite Softening Demand for Covid Products

1 aug. 2024, 11:50 UTC

Câștiguri

Regeneron Stock Climbs After Strong Second-Quarter Performance -- IBD

1 aug. 2024, 10:37 UTC

Câștiguri

Regeneron Pharma 2Q Adj EPS $11.56 >REGN

1 aug. 2024, 10:30 UTC

Câștiguri

Regeneron Pharma 2Q EPS $12.41 >REGN

1 aug. 2024, 10:30 UTC

Câștiguri

Regeneron Pharma 2Q Net $1.43B >REGN

1 aug. 2024, 10:30 UTC

Câștiguri

Regeneron Pharma 2Q Rev $3.55B >REGN

20 iun. 2024, 20:16 UTC

Top știri

Why Wall Street Is Chasing Ozempic Wannabes -- Heard on the Street -- Update

20 iun. 2024, 18:09 UTC

Top știri

Why Wall Street Is Chasing Ozempic Wannabes -- Heard on the Street -- Update

20 iun. 2024, 11:00 UTC

Top știri

Why Wall Street Is Chasing Ozempic Wannabes -- Heard on the Street -- WSJ

2 mai 2024, 10:32 UTC

Câștiguri

Regeneron Pharma Cuts 2024 Capital Spending View to $780M-$880M From $825M-$950M >REGN

2 mai 2024, 10:32 UTC

Câștiguri

Regeneron Pharma Still Sees 2024 Adjusted Gross Margin 89%-91% >REGN

2 mai 2024, 10:31 UTC

Câștiguri

Regeneron Pharma Sets New $3 Billion Share-Repurchase Program >REGN

2 mai 2024, 10:30 UTC

Câștiguri

Regeneron Pharma 1Q Rev $3.15B >REGN

2 mai 2024, 10:30 UTC

Câștiguri

Regeneron Pharma 1Q Adj EPS $9.55 >REGN

2 mai 2024, 10:30 UTC

Câștiguri

Regeneron Pharma 1Q EPS $6.27 >REGN

2 mai 2024, 10:30 UTC

Câștiguri

Regeneron Pharma 1Q Net $722M >REGN

11 apr. 2024, 13:47 UTC

Acțiuni populare

Stocks to Watch Thursday: Robinhood, Alpine Immune, Constellation Brands -- WSJ

5 feb. 2024, 12:00 UTC

Top știri

What a $200 Billion Blockbuster Drug Reveals About Big Pharma's Playbook -- Heard on the Street -- WSJ

2 feb. 2024, 17:05 UTC

Câștiguri

Regeneron Earnings Beat Forecasts as Sales of Updated Eye Drug Raise Hopes -- Barrons.com

2 feb. 2024, 14:13 UTC

Câștiguri

The Surprising Sources Of Regeneron's Fourth-Quarter Beat As Shares Hit Another Record High -- IBD

2 feb. 2024, 11:36 UTC

Câștiguri

Regeneron Pharma Sees 2024 Capital Spending $825M-$950M >REGN

2 feb. 2024, 11:36 UTC

Câștiguri

Regeneron Pharma Sees 2024 Adjusted Gross Margin 89%-91% >REGN

2 feb. 2024, 11:36 UTC

Câștiguri

Regeneron Pharma Sees 2024 Adjusted R&D Spending $4.3B-$4.5B >REGN

2 feb. 2024, 11:31 UTC

Câștiguri

Regeneron Pharma: 4Q Dupixent Global Sales, Recorded by Sanofi, Rose 31% to $3.22B >REGN

2 feb. 2024, 11:31 UTC

Câștiguri

Regeneron Pharma 4Q U.S. Eylea HD, Eylea Sales $1.46B >REGN

2 feb. 2024, 11:30 UTC

Câștiguri

Regeneron Pharma 4Q EPS $10.19 >REGN

2 feb. 2024, 11:30 UTC

Câștiguri

Regeneron Pharma 4Q Rev $3.43B >REGN

2 feb. 2024, 09:37 UTC

Câștiguri

These Stocks Are Moving the Most Today: Meta, Amazon, Apple, Intel, Deckers, Skechers, Clorox, and More -- Barrons.com

Comparație

Modificare preț

Regeneron Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

2.78% sus

Prognoză pe 12 luni

Medie 1,185.39 USD 2.78%

Maxim 1,300 USD

Minim 870 USD

În baza a 20 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruRegeneron Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

20 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 20 analiști care au acordat evaluări ale acțiunilor Regeneron Pharmaceuticals Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

1143.245 / 1162.865Suport & Rezistență

Recent bullish events outweigh bearish events.

There is one bullish event.

There are no events.

Sentiment

By Acuity

284 / 365 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious diseases. The Company commercializes medicines and product candidates for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, Kevzara (sarilumab) Solution for Subcutaneous Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion.